Rational design and efficacy of a multi-epitope recombinant protein vaccine against foot-and-mouth disease virus serotype A in pigs

Cao, Yimei; Li, Dong; Fu, Yuanfang; Bai, Qiang; Chen, Yingli; Bai, Xingwen; Jing, Zhizhong; Sun, Pu; Bao, Huang; Li, Pinghua; Zhang, Jing; Ma, Xueqing; Lu, Zengjun; Liu, Zaixin

doi:10.1016/j.antiviral.2017.01.023

Cited by 44 publications

(34 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…overlapping CTL, HTL and B cell epitopes have the capacity to activate humoral and cellular immune responses simultaneously, iii) linking an adjuvant to the vaccine ensures a long lasting immune response with enhanced immunogenicity, iv) the in vitro antigen expression complications as well as the difficulty of culturing the pathogens can also be avoided [35][36][37][38][39][40][41][42][43]. Designing of multi-epitope vaccines is an emerging area which has already gained importance, and the vaccines designed by this approach, have not only shown in vivo efficacy with protective immunity [44][45][46] but also entered phase-I clinical trials [39,40,47,48].…”

Section: Immune Simulationmentioning

confidence: 99%

A Candidate multi-epitope vaccine against SARS-CoV-2

Narsaria

Basak

et al. 2020

Preprint

View full text Add to dashboard Cite

In the past two decades, 7 coronaviruses have infected the human population, with two major outbreaks caused by SARS-CoV and MERS-CoV in the year 2002 and 2012, respectively. Currently, the entire world is facing a pandemic of another coronavirus, SARS-CoV-2, with a high fatality rate. The spike glycoprotein of SARS-CoV-2 mediates entry of virus into the host cell and is one of the most important antigenic determinants, making it a potential candidate for a vaccine. In this study, we have computationally designed a multi-epitope vaccine using spike glycoprotein of SARS-CoV-2. The overall quality of the candidate vaccine was validated in silico and Molecular Dynamics Simulation confirmed the stabilityof the designed vaccine. Docking studies revealed stable interactions of the vaccine with Toll Like Receptors and MHC Receptors. Codon optimization was used to optimize high expression of the vaccine in E.coli K-12 strain. In silico cloning suggested efficient expression in pET-28a (+) vector. The efficiency of the candidate vaccine to trigger an effective immune response was assessed by an in silico immune simulation. The computational analyses suggest that the designed multi-epitope vaccine is structurally stable which can induce specific immune responses and thus, can be a potential vaccine candidate against SARS-CoV-2.Authors Tamalika Kar, Utkarsh Narsaria, Srijita Basak, and Debashrito Deb contributed equally to this work.

show abstract

Section: Immune Simulationmentioning

confidence: 99%

A Candidate multi-epitope vaccine against SARS-CoV-2

Narsaria

Basak

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Developing universal vaccines effective against various subtypes of influenza is the primary approach for controlling the spread of infection (22). As epitopes are a key feature of viruses, several strategies have been successfully applied in the design and development of ‘epitope-focused’ vaccines (23,24), which demonstrate advantages such as high specificity, fewer side effects, simple preparation, and easy storage and transportation (25,26). These rapid and accurate strategies have become the foundation for the development of influenza virus vaccines, as well as supporting clinical diagnosis and treatment.…”

Section: Discussionmentioning

confidence: 99%

H1N1 influenza virus epitopes classified by monoclonal antibodies

et al. 2018

View full text Add to dashboard Cite

Epitopes serve an important role in influenza infection. It may be useful to screen universal influenza virus vaccines, analyzing the epitopes of multiple subtypes of the hemagglutinin (HA) protein. A total of 40 monoclonal antibodies (mAbs) previously obtained from flu virus HA antigens (development and characterization of 40 mAbs generated using H1N1 influenza virus split vaccines were previously published) were used to detect and classify mAbs into distinct flu virus sub-categories using the ELISA method. Following this, the common continuous amino acid sequences were identified by multiple sequence alignment analysis with the GenBank database and DNAMAN software, for use in predicting the epitopes of the HA protein. Synthesized peptides of these common sequences were prepared, and used to verify and determine the predicted linear epitopes through localization and distribution analyses. With these methods, nine HA linear epitopes distributed among different strains of influenza virus were identified, which included three from influenza A, four from 2009 H1N1 and seasonal influenza, and two from H1. The present study showed that considering a combination of the antigen-antibody reaction specificity, variation in the influenza virus HA protein and linear epitopes may present a useful approach for designing effective multi-epitope vaccines. Furthermore, the study aimed to clarify the cause and pathogenic mechanism of influenza virus HA-induced flu, and presents a novel idea for identifying the epitopes of other pathogenic microorganisms.

show abstract

“…With the exception of serotype C, other serotypes have been found to be prevalent, among which type A and type O are the most widespread, primarily in Asia, Africa, and the Middle East . Among the seven known FMDV serotypes, type A and type O are also prevalent in China, and type Asia I has been successfully controlled …”

Section: Introductionmentioning

confidence: 99%

“…8,9 Among the seven known FMDV serotypes, type A and type O are also prevalent in China, and type Asia I has been successfully controlled. 10 Currently, vaccine immunization remains the primary method of preventing and controlling FMDV, and a commercial inactivated vaccine remains the most widely used vaccine. 3 However, inactivated vaccines are also associated with several disadvantages, such as the risk of spreading virus in the course of production and use, and the high manufacturing cost.…”

mentioning

confidence: 99%

“…11 In addition, with the development of genetic engineering technology, the research and development of a new FMDV subunit vaccine has made substantial advances (eg, synthetic peptide vaccine, multi-epitope vaccine, and virus-like particle [VLP] vaccines). 10,[12][13][14] FMDV is primarily recognized by the host via a conservative RGD motif on the VP1 G-H loop (amino acid residues 130-160); thus, the G-H loop on VP1 represents the most important protective antigen and plays an important role in generating neutralizing antibodies against FMDV. 15,16 As early as the last century, Bittle et al 15 immunized animals with the synthesized 141-160 aa peptide of VP1, which promoted the production of neutralizing antibodies against FMDV infection, thus initiating FMDV epitope vaccine research.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate

Yao

Shao

Zhao

et al. 2019

Journal of Medical Virology

View full text Add to dashboard Cite

Recently, many countries, including China, have experienced a series of type A and O foot‐and‐mouth disease virus (FMDV) epidemics, causing serious economic losses. Although concerns about the safety of inactivated FMD vaccines have been raised, the development of a safe and effective subunit vaccine is necessary. We constructed two chimeric virus‐like particles (VLPs; rHBc/AO and rHBc/AOT VLPs) displaying tandem repeats of B cell epitopes (VP1 residue 134‐161 and 200‐213) derived from type A and O FMDV and one T cell epitope (3 A residue 21‐35) using the truncated hepatitis B virus core (HBc) carrier. Our results indicate that the chimeric HBc can self‐assemble into VLPs with these FMDV epitopes displayed on the surface. Immunization with the chimeric VLPs induced specific IgG and neutralization antibodies against type A and O FMDV in mice. Compared with the commercial type A/O FMDV bivalent inactivated vaccine, rHBc/AO and rHBc/AOT VLPs significantly stimulated the production of Th1 type cytokines (IFN‐γ and IL‐2), whereas Th2 cytokine production (IL‐4 and IL‐10) was decreased. Compared with rHBc/AO, rHBc/AOT induced increased Th2 cytokine and specific IgG production. These results demonstrate that the VLPs constructed in the current study induced both humoral and cellular immune responses and may represent potential bivalent VLP vaccines targeting both FMDV type A and O strains.

show abstract

Rational design and efficacy of a multi-epitope recombinant protein vaccine against foot-and-mouth disease virus serotype A in pigs

Cited by 44 publications

References 37 publications

A Candidate multi-epitope vaccine against SARS-CoV-2

A Candidate multi-epitope vaccine against SARS-CoV-2

H1N1 influenza virus epitopes classified by monoclonal antibodies

Artificially designed hepatitis B virus core particles composed of multiple epitopes of type A and O foot‐and‐mouth disease virus as a bivalent vaccine candidate

Contact Info

Product

Resources

About